Although cell therapy improves cardiac function after myocardial infarction, highly variable results and limited understanding of the underlying mechanisms preclude its clinical translation. Because many heart failure patients are diabetic, we examined how diabetic conditions affect the characteristics of cardiac mesenchymal cells (CMC) and their ability to promote myocardial repair in mice. To examine how diabetes affects CMC function, we isolated CMCs from non-diabetic C57BL/6J ( , n = 17; CMC db/db , n = 13; Veh, n = 14). Hemodynamic measurements performed 35 days after transplantation showed that, despite normalization of their properties in vitro, and unlike CMC WT cells, CMC db/db cells did not improve load-dependent and -independent parameters of left ventricular function. These results suggest that diabetes adversely affects the reparative capacity of CMCs and that modulating CMC characteristics via culture in lower glucose does not render them efficacious for cell therapy.
Introduction
Cell therapy is a potential treatment for restoring cardiac function in heart failure patients. Promising results with animal models and in humans suggest that cell transplantation after myocardial infarction (MI) improves cardiac function, which is associated with decreased scar size, angiogenesis, or increased viable tissue [4, 5, 12, 24, 25, 41, 49, 50, 59, 60, 69, 71, 73] . Nevertheless, the ability of cells isolated from diabetic hearts to promote cardiac recovery remains unclear. Previous work has shown that diabetes inhibits the ability of numerous types of cells to promote tissue repair. For example, diabetes diminishes the ability of cardiac progenitor cells (CPCs) [44, 54, 57] , endothelial progenitor cells, mesenchymal stem cells and hematopoietic stem cells [16, 17, 30, 31, 36, 55, 64] to migrate, proliferate, secrete paracrine factors, differentiate or engraft [2, 3, 7, 15, 18, 29, 33, 38, 39, 42, 63, 68, 77, 80] . This is significant because, in the US, ~ 25% of heart failure patients are diabetic, and up to 65% of hospitalized HF patients have type 2 diabetes (T2D) [14, 58, 61] . Therefore, understanding the mechanisms by which T2D affects cell therapy could provide a conceptual framework Electronic supplementary material The online version of this article (https ://doi.org/10.1007/s0039 5-018-0703-0) contains supplementary material, which is available to authorized users.
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for improving the reparative properties of multiple cell types for patients with or without metabolic disease.
In diabetes, systemic insulin resistance-leading to poor glucose control and hyperglycemia-could negatively affect several cell types, particularly cells with mesenchymal characteristics. Cells of mesenchymal origin typically do not require insulin for glucose uptake (e.g., CPCs [56, 57] ), leaving them exceptionally vulnerable to hyperglycemic injury. Accordingly, the purpose of this study was to examine whether diabetes damages the mesenchymal cell pool, which represents a common source of cells used for transplantation, and whether modifying culture conditions might render them efficacious for therapy. We found that cardiac mesenchymal cells (CMCs) [21, 72, 73] from the db/db diabetic mouse model (CMC db/db ) show marked metabolic derangements that mirror those found in diabetic CPCs [57] . Passaging of CMC db/db cells in low glucose conditions normalizes their metabolic profile and robustly augments the expression of Sirt1. Despite this, correction of CMC dbdb properties via culture in low glucose was not sufficient to render them suitable for cardiac repair.
Materials and methods

Cell isolation and culture
All animal procedures were performed in compliance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the University of Louisville Institutional Animal Care and Use Committee. The CMCs were isolated from 3-month-old male B6.BKS(D)-Lepr db /J (db/db) and C57BL/6 J wildtype (WT) mice (Jackson Laboratories, Bar Harbor, ME) without sorting for surface markers such as c-kit [73] . This procedure for cell isolation has been described before [72] . Briefly, excised hearts were washed in PBS and enzymatically dissociated with Collagenase II (5 mg/mL in PBS; Worthington) by gentle agitation for 45 min at 37 °C. After Collagenase II inactivation with DMEM/F12 medium containing 10% FBS, the cells were centrifuged at 600 g for 10 min. The collected cell pellet was suspended in growth medium consisting of DMEM/F12 (Invitrogen) containing 17.5 mM glucose, 10% FBS (Seradigm, VWR), bFGF (10 ng/ml), EGF (10 ng/ml), ITS (insulin/transferrin/selenium), glutamine, and penicillin-streptomycin. The CMCs were cultured and passaged twice in this growth medium. The cells were then frozen in liquid nitrogen. Upon thawing, the cells were propagated in the same growth medium containing either 5.5 mM or 17.5 mM glucose for 2-5 passages prior to in vitro or in vivo experiments.
Flow cytometry
Expression of cell surface markers was assessed by flow cytometry. Harvested CMCs (passage 3-6) were blocked with FcBlock (0.005 mg/ml in PBS containing 11% BSA) for 10 min at 4 °C. The CMCs were stained with the antibodies (eBioscience) listed in Supplementary Table 1. Data were acquired on an LSRII flow cytometer (BD BioSciences) using BD FACSDiva software and analyzed using FlowJo software. Unstained samples were used for setting discrimination gates.
Proliferation and cytotoxicity measurements
Cell proliferation was assessed by counting cells using a hemocytometer, as described previously [56] . Cell viability and cytotoxicity was assessed by lactate dehydrogenase assay, as described previously [56] .
Gene expression and protein abundance analyses
Gene expression was assessed by measuring cell type-specific gene expression by qRT-PCR. For qRT-PCR, mRNA was isolated from CMCs using TRIZOL reagent (Invitrogen) and RNA quantity and purity were estimated by measuring absorbances at 260 and 280 nm using a Nanodrop spectrophotometer (Thermo scientific). Two µl of cDNA was used in a reaction mixture containing SYBR green (VWR) and oligo primers (Integrated DNA Technologies, Inc). The Pfkfb3 primers used for qRT-PCR are forward primer, GTG ACA GGG ACT TGT CAC TC; reverse primer, GCC ATG CCG ACA CAG GTA.
For Western blotting, protein from CMC lysates was applied to each lane of a 12.5% or 10.5-14% Bis-Tris-HCl gel and electrophoresed. The separated proteins were then electroblotted onto a PVDF membrane and immunoblotted as described [56, 57] . The following antibodies were used for these studies: anti-Sirt1 antibody (Cell Signaling Technology; 2496S), anti-Sirt3 antibody (Cell Signaling Technology; 5490S), anti-Sirt6 antibody (Cell Signaling Technology; 12486S) and anti-β-actin antibody (Cell Signaling Technology; 12262S). Immunoreactive bands were detected using a Fuji LAS-3000 Bio Imaging analyzer after exposure to ECL detection reagent. Band intensities were quantified using TotalLab TL120 or ImageQuantTL software.
Extracellular vesicle (EV) isolation
CMC-derived EVs were isolated using previously published protocols [10, 34, 65] . Briefly, CMCs were cultured in growth medium. At 80% confluency, the cells were washed in PBS and suspended in basal DMEM/F12 media supplemented with 0.5% BSA. After 24 h, conditioned media were collected and centrifuged (3000g, 15 min, 4 °C) to pellet cells and large debris. The EVs in the supernatant were precipitated with one-third volume of polyethylene glycol (PEG) buffer (33.4% w/v PEG 4000, 50 mM HEPES [pH 7.4], 1 mM NaCl) overnight at 4 °C, followed by centrifugation at 3000g for 30 min. The EV pellets were resuspended in PBS and then centrifuged at 100,000g (Beckman Coulter Optima L-90 K ultracentrifuge) for 2 h at 4 °C.
miRNA array
Total RNA was isolated from EVs using the mirVana™ miRNA Isolation Kit (Ambion). A rodent miRNA microarray kit (Applied Biosystems) was used to assess the miRNA profile according to the manufacturer's protocol. Briefly, 350 ng of total RNA (combined RNA from three independent isolations) was reverse-transcribed with Megaplex RT primers (Megaplex RT Rodent Pool A) and pre-amplified using Megaplex PreAmp primers followed by a real-time PCR with a TaqMan Rodent MicroRNA Array (panel A) performed on an Applied Biosystems ViiA™ 7 Real-Time PCR System. SDS software version 2.3 (Applied Biosystems) was used to obtain the comparative threshold cycle (Ct) value. U6 small nuclear RNA included in the TaqMan Rodent MicroRNA Array was used as an endogenous control and the relative expression was calculated using the ΔΔCt method.
Extracellular flux analysis
Mitochondrial activity and surrogate measures of glycolytic flux were measured in WT and db/db CMCs, using procedures described previously [27, 56, 57] .
Radiometric determination of glycolytic flux
Glycolytic flux was determined by analyzing the conversion of [5- 3 H]-glucose to [ 3 H] 2 O, as described previously [19, 56, 57] .
Stable isotope tracing
Isolated WT and db/db CMCs were incubated with 5.5 mM 13 C 6 -glucose in 6-well plates for 12 h, quenched in cold acetonitrile, and extracted in acetonitrile:water:chloroform (v/v 2:1.5:1), similar to that described previously [19, 57] . Lipid and nucleotide spectra were acquired using a hybrid linear ion trap-FT-ICR mass spectrometer (Finnigan LTQ FT, Thermo Electron), as described previously [19, 57] . The FT-ICR MS spectra were exported as exact mass lists into a spreadsheet file using QualBrowser 2.0 (Thermo Electron).
Assignments of all isotopologue peaks of metabolites were performed based on their accurate mass matching (m/z window ± 3 ppm), and natural isotope abundance contributions from each of the isotopologues in the MS data were stripped using MetSign [19, 57, 67] . To calculate relative abundances of NAD + , NADH, and adenine nucleotides, the intensities of each spectral peak for each individual metabolite were summed. These total abundances were then used to calculate NAD + /NADH ratios and relative adenylate abundances.
Murine model of myocardial infarction
C57BL6/J female mice (12 weeks of age), purchased from The Jackson Laboratory (Bar Harbor, ME, USA) [74] , were maintained under specific pathogen-free conditions and a 12-h light-dark cycle. Food and water were provided ad libitum. For ischemia-reperfusion, mice were anesthetized with sodium pentobarbital (60 mg/kg i.p.). The chest was opened through a midline sternotomy, and a nontraumatic balloon occluder was implanted around the mid-left anterior descending coronary artery using an 8-0 nylon suture. Rectal temperature was carefully monitored and maintained between 36.7 and 37.3 °C throughout the experiment. In all groups, MI was produced by a 60-min coronary occlusion followed by reperfusion. Successful performance of coronary occlusion and reperfusion was verified by visual inspection and by observing S-T segment elevation and widening of the QRS on the electrocardiogram during ischemia and their resolution after reperfusion.
Preparation of cells for injection
The CMCs were expanded for 3-5 passages in growth medium containing 5.5 mM glucose. On the day of injection, cells were 60-80% confluent. The cell monolayer was washed two times with room temperature PBS, and the cells were harvested by enzymatic digestion with 0.25% trypsin-EDTA (Invitrogen). The resulting cell suspension was trypsin-inactivated with DMEM/F12 supplemented with 10% FBS. After centrifugation at 600g for 10 min at room temperature (RT), the cells were suspended in PBS and counted using a hemocytometer. Next, the cells were filtered through a 40-μm filter and centrifuged for 10 min at 600g at RT. An aliquot of 2.5 × 10 6 cells was suspended in 1000 µL of sterile PBS (pH 7.4) at room temperature and transported to the mouse surgery laboratory for injection.
Intramyocardial cell delivery
At 48 h after I/R, the mice were anesthetized and the chest reopened through a central thoracotomy. The CMCs (10 5 cells in 40 μL) or, an equivalent volume of vehicle, were injected intramyocardially using a 30-gauge needle. A total of four injections (10 μL each) were made in the peri-infarct region in a circular pattern, at the border between infarcted and noninfarcted myocardium, as described [73] .
Invasive hemodynamic measurements
Left ventricular (LV) mechanical performance was assessed using a Millar pressure-conductance catheter 35 days after cell transplantation, as described [73] . The hemodynamic studies were performed just before euthanasia using a MPVS Ultra pressure-volume (PV) loop system (Millar Instruments) and 1.0 French PVR-1035 microtip ultra-miniature PV catheters (Millar Instruments). Mice were anesthetized with sodium pentobarbital (60 mg/kg, i.p.) and rectal temperature kept between 36.7 and 37.3 °C. A 1.0 French Millar catheter was inserted into the LV via the right carotid artery. After 30 min stabilization, the PV signals were recorded continuously. Inferior vena cava occlusion was performed with external compression to produce variably loaded beats for determination of LV performance. The LabChart 7 Pro data acquisition and analysis software (with built-in PV loop module; AD Instruments) was used to calculate cardiovascular parameters.
Statistical analysis
All values are mean ± SEM. All comparisons were made to the relevant control group, and statistical tests were performed using either t test or one-way analysis of variance (ANOVA) with Bonferroni correction for multiple comparisons [35] . The null hypothesis was rejected when p > 0.05.
Results
Diabetic CMCs demonstrate a higher reliance on glycolysis
We first examined the cell surface marker expression profile of CMC WT and CMC db/db cells. Both cell types expressed similar profiles of the mesenchymal markers CD90.2, CD29, and CD105. Both preparations also showed ~ 80% positivity for Sca-1 and ~ 15% positivity for CD34. Similar to diabetic CPCs [57] , CD73 expression appeared lower in CMC db/db cells; however, further analysis in four independent isolations showed no statistical significance for CD73 abundance (CMC WT : 60.2 ± 6.6%; CMC db/db : 45.6 ± 6.1%, p > 0.05). The cells were mostly negative for CD31, c-kit, and CD45 (Fig. 1) .
To determine whether diabetes affects the metabolic characteristics of CMCs (similar to that of CPCs [57] ), we measured mitochondrial activity and extracellular acidification rates (ECAR) in CMC WT and CMC db/db cells (Fig. 2a) . The CMC db/db cells showed lower basal oxygen consumption rates (OCR; Fig. 2b ) and a > twofold increase in basal ECAR (Fig. 2c) . The lower OCR/ECAR ratio in CMC db/db cells suggests lower reliance on oxidative phosphorylation for energy (Fig. 2d) . Consistent with findings in diabetic CPCs [57] , CMC db/db cells had threefold higher expression of Pfkfb3 (Fig. 2e) , which encodes an enzyme known to activate glycolysis [45, 57, 75] . Collectively, these findings indicate that diabetes promotes a glycolytic phenotype in slowly adherent CMCs, which is similar to its effects on CPCs.
Culture of CMC db/db cells in low glucose normalizes their metabolic profile
Typical growth medium for mouse CMC and CPC culture contains 17.5 mM glucose, which is hyperglycemic (315 mg/dl) in mammals. Therefore, we examined whether culturing the CMC cells in low glucose conditions (i.e., 5.5 mM, simulating 99 mg/dl) might improve the metabolic profile of CMCs. For this, CMC WT and CMC db/db cells that were isolated in 17.5 mM glucose-containing medium were cultured in low (5.5 mM) glucose-containing medium and passaged twice over the course of 2 weeks (Fig. 3a) . We then examined the metabolism of the CMCs to determine if metabolic changes in CMC db/db cells persist upon switching from 17.5 to 5.5 mM glucose. Surprisingly, we found no differences in OCR or ECAR between CMC WT and CMC db/db cells ( Fig. 3b-d) . Furthermore, glycolytic flux measured via the tritiated glucose assay was not different between the groups (Fig. 3e) . Moreover, Pfkfb3 expression levels were similar in both cell preparations (Fig. 3f) .
To assess metabolism in the cells further, we cultured both cell preparations in medium containing 5.5 mM 13 C 6 -glucose for 12 h and performed stable isotope resolved metabolomics. As shown in Suppl. Figure 1 , end products of ancillary biosynthetic pathways of glucose metabolism, such as those from the pentose phosphate pathway (e.g., ATP), the hexosamine biosynthetic pathway (i.e., UDP-Glc(Gal)NAc), and the glycerophospholipid pathway (e.g., phosphatidylinositol), showed no differences in 13 C labeling. Similarly, we found no differences in labeling of other phospholipids and nucleotides (data not shown). Because cells of mesenchymal origin may also use glutamine as a fuel source [56] , we also incubated cells in 15 N 2 13 C 5 -glutamine for 12 h and assessed labeling. We found no differences in labeling of the detected metabolites (data not shown). Taken together, these data indicate that the diabetes-induced changes in metabolism in CMC db/db cells are normalized upon culture in medium containing 5.5 mM glucose.
Culture of CMC db/db cells in low glucose medium upregulates Sirt1
Although (Fig. 4) . Sirt3 expression was unchanged in both conditions (data not shown).
Given that Sirt1 regulates nutrient signaling, promotes mitochondrial biogenesis, prevents senescence, improves cell survival, combats oxidative stress, and diminishes genomic instability [9, 40, 43, 62, 70] , we next assessed proliferation of the CMC WT and CMC db/db cells cultured in low glucose and examined their viability after a 16 h challenge with hydrogen peroxide. As shown in Fig. 5a and 5b, doubling time and cell viability were not statistically different between CMC WT and CMC db/db cells. However, extracellular vesicles (EVs) isolated from the culture medium (Fig. 5c) , including miR-182, which has been shown to both upregulate Sirt1 and be a downstream effector of Sirt1, regulating nerve regeneration [66] .
Low glucose culture of CMC db/db cells does not restore their therapeutic efficacy
That low glucose culture of CMC db/db cells rendered them metabolically and functionally similar to CMC WT cells in vitro as well as upregulated Sirt1 and influenced EV cargo suggested to us that their reparative properties in vivo may be similarly influenced. To test this hypothesis, we injected CMC WT and CMC db/db that were acclimated to low glucose culture conditions into the border zone of the infarcted murine heart. The cells (or vehicle) were injected 48 h after I/R injury, and cardiac function was assessed after 35 days (Fig. 6a) . Just prior to euthanasia, we performed hemodynamic assessment of LV function using a pressure-volume catheter. Similar to our previous reports [73] , CMC WT cells improved the load-dependent parameters of LV ejection fraction and dP/dt as well as the load independent parameter, end-systolic elastance; however, CMC db/db cells failed to improve LV function (Fig. 6b-e) . Collectively, these data demonstrate that the apparent improvement of CMC db/db cell competence caused by 5.5 mM glucose culture in vitro does not extend to reparative efficacy in vivo.
Discussion
Our previous studies suggest that CMCs isolated on the basis of their adherent properties exhibit robust reparative properties [73] . In this study, we examined whether diabetes affects this population of cells in a manner similar to that of CPCs, which are sensitive to hyperglycemic damage [44, 54, 56, 57] . We found that, like CPCs isolated from diabetic mice, CMC db/db cells show higher levels of glycolysis, which may be related in part to upregulation of Pfkfb3. Because murine CPCs and CMCs are typically cultured in hyperglycemic (17.5 mM glucose) medium, we tested whether switching cells a lower glucose (5.5 mM) medium would restore metabolic defects and render them efficacious for myocardial repair. We found that culturing the cells in 5.5 mM glucose fully normalized catabolic and anabolic CMC metabolism, robustly upregulated Sirt1, and changed the miRNA profile in EVs. Despite this apparent improvement in metabolic profile, the CMCs were ineffective for cardiac repair, which suggests that the impact of diabetes on the reparative qualities of In vitro competency factors of CMC WT and CMC db/db cells grown in low glucose medium. CMCs isolated from WT and db/db mice were expanded in low glucose medium for two passages and the following competency factors were examined: a Cell proliferation; b cytotoxicity caused by incubation with 500 µM hydrogen peroxide. n = 3 biological replicates per group; and c miRNA (miR) analysis in extracellular vesicles isolated from the culture medium. Data are derived from pooled samples of 3 biological replicates per group CMCs extends beyond short-term changes in intermediary metabolism.
Our findings that reparative defects persist in CMCs despite normalization of glucose metabolism is, in a general sense, consistent with results of the ADVANCE and ACCORD trials, which show that strict glucose control does not diminish the macrovascular and cardiac complications of diabetes [1, 20] . Lack of efficacy of CMC db/db cells could be explained via persistence of hyperglycemia-induced defects. This phenomenon is termed metabolic memory-a hypothesis that cells and tissues remember their glycemic environment [8] . The mechanisms underlying metabolic memory in diabetes are thought to involve mitochondrial dysfunction [48] and flooding of ancillary biosynthetic pathways [6] . Our data show that culture of CMC db/db cells in medium containing 5.5 mM glucose normalized glycolysis, mitochondrial activity, and biosynthetic pathway activity, which indicates that acute reversal of metabolic abnormalities caused by diabetes does not render CMCs effective in myocardial repair.
A remarkable consequence of switching CMC db/db cells to low glucose medium was stark upregulation of Sirt1, which was accompanied by a modest downregulation of Sirt6. This is interesting because sirtuins regulate metabolism: both Sirt1 and Sirt6 affect glycolytic and mitochondrial activity [23, 52, 81] . We speculate that culturing CMC db/db cells in medium containing 5.5 mM glucose leads to a form of energy restriction, which promotes upregulation of Sirt1 and normalizes metabolism. This notion would be consistent with previous studies showing that glucose restriction (or calorie restriction) upregulates Sirt1 and promotes metabolic remodeling in cultured cells as well as in whole organisms (e.g., [22, 26, 32, 78] 47, 76] and that it can improve cardiac repair after injury [13, 79] . In addition, it is also worth noting that mesenchymal stem cells cultured for up to 12 h without glucose showed higher cardiac repair capacity than cells cultured with glucose [11] , which further strengthened our rationale for testing the 5.5 mM glucose culture strategy. Despite these expectations, our in vivo studies showed that CMC db/db cells cultured in low glucose failed to improve cardiac function, even though they showed improvement in not only metabolic parameters, but also indices commonly related to cell competence. The CMC db/db cells cultured in 5.5 mM glucose showed similar, if not slightly improved, proliferation and viability in vitro compared with CMC WT cells cultured under the same conditions. Furthermore, analysis of nucleic acid cargo in EVs isolated from CMC db/db cells showed numerous upregulated miRNAs including miR-182, which has been shown to be upregulated in a SIRT1-dependent manner and to promote corneal nerve regeneration [66] . Moreover, several other miRNAs that were in higher abundance in CMC db/db -derived EVs have been shown to have beneficial actions. For example, the levels of miR-15a, mi339-5p, and mi-370 were higher in EVs derived from CMC db/db cells, and these are thought to be involved in tissue regeneration or fibrosis [37, 51, 53] . That these in vitro measures of cell competence do not equate to in vivo efficacy is an important outcome of this study that merits further investigation.
In summary, our study shows that even though CMCs are effective in promoting cardiac repair, their reparative capacity is severely compromised by diabetes. We found that culturing diabetic cells (CMC db/db cells) in what is typically considered normal glucose (5.5 mM) restores their metabolic activity to levels similar to that of CMC WT cells and augments Sirt1 levels. Despite these changes, CMC db/db cells were ineffective in promoting cardiac repair. These observations suggest that diabetes induces deleterious changes to CMCs that are difficult to reverse. Future studies are required to determine whether diabetes-induced attenuation of CMC-mediated repair is due to other factors, such as an inability to promote an adequate immune response.
